To this point, the National Institute for Health and Care Excellence (NICE) Single Technology Appraisal (STA) process was applied in order to evaluate the cost-effectiveness and to identify the most suitable subgroup of cancer patients who would be eligible to receive albumin-bound paclitaxel and gemcitabine (Nab-Pac + Gem) for pancreatic cancer treatment. Here, ALB is linked to familial pancreatic carcinoma.